Continue the Conversation

ACR Convergence 2024: Continue the Conversation

Questions discussed in this category

How do you incorporate smart phone microscopy into your clinical assessment of Raynaud's?

How do you document this? This question is part of our collaboration with ACR Convergence 2025 to Continue the Conversation from the meeting. This qu...

2 Answers available

How often do you perform nailfold capillaroscopy in your clinical practice in patients with CTD?

This question is part of our collaboration with ACR Convergence 2025 to Continue the Conversation from the meeting. This question was inspired by the ...

2 Answers available

What are some practical tips for eliciting an accurate history of Raynaud's phenomenon in patients being assessed for CTD?

This question is part of our collaboration with ACR Convergence 2025 to Continue the Conversation from the meeting. This question was inspired by the ...

3 Answers available

How do you incorporate hyperbaric oxygen therapy into the care of patients with wounds related to ischemic ulcerations?

What additional workup or assessment is necessary prior to recommending this therapy? This question is part of our collaboration with ACR Convergence...

2 Answers available

In which patients with SSc do you add anti-platelet therapy and/or statins for Raynaud's phenomenon?

This question is part of our collaboration with ACR Convergence 2025 to Continue the Conversation from the meeting. This question was inspired by the ...

2 Answers available

Do you recommend vasodilators in patients with Raynaud's who have capillary drop out but are otherwise not bothered enough by their symptoms to want to pursue systemic treatment?

This question is part of our collaboration with ACR Convergence 2025 to Continue the Conversation from the meeting. This question was inspired by the ...

3 Answers available

When should bone biopsy be considered to guide management in patients in whom you're differentiating osteoporosis and renal osteodystrophy?

This question is part of our collaboration with ACR Convergence 2025 to Continue the Conversation from the meeting. This question was inspired by the ...

1 Answer available

How would you manage a patient with discordant TBS adjusted T-score and traditional T-score?

When a TBS-adjusted T-score suggests someone may actually be in the osteoporotic range, but the traditional T-score does not, would you treat the pati...

2 Answers available

Do you find trabecular bone score (TBS) useful in patients with a history of ankylosing spondylitis when screening for vertebral fracture risk?

This question is part of our collaboration with ACR Convergence 2025 to Continue the Conversation from the meeting. This question was inspired by the ...

2 Answers available

How does an incidental finding of low bone density on imaging done for another reason inform your screening approach for osteoporosis?

For example, if this comes back in a hand X-ray report, do you generally follow this up with a formal DEXA screening, assuming the patient has not rec...

2 Answers available

How do you approach the diagnostic evaluation of osteoporosis in CKD when renal dysfunction limits use of certain tests or biomarkers?

This question is part of our collaboration with ACR Convergence 2025 to Continue the Conversation from the meeting. This question was inspired by the ...

1 Answer available

What is your approach to screening patients with sJIA for associated lung disease?

Do you universally screen? What prompts you to screen when you do? This question is part of our collaboration with ACR Convergence 2024 to Continue t...

1 Answer available

What is the most impactful career advice you have received from a colleague or mentor?

This question is part of our collaboration with ACR Convergence 2024 to Continue the Conversation from the meeting. This question was inspired by the ...

6 Answers available

What strategies or initiatives do you think could be most effective in addressing the rheumatology workforce shortage?

This question is part of our collaboration with ACR Convergence 2024 to Continue the Conversation from the meeting. This question was inspired by...

3 Answers available

How do you screen rheumatoid arthritis patients for lung disease (modality, frequency, patient selection)?

This question is part of our collaboration with ACR Convergence to Continue the Conversation from the meeting.

5 Answers available

How long do you continue rituximab in patients with ANCA associated vasculitis who have achieved remission?

What information do you use to make this determination? Do you tend to transition to an oral agent like azathioprine after discontinuation to prevent ...

2 Answers available

How do you determine which patients with ANCA associated vasculitis may be good candidates for reduced dose glucocorticoid tapering?

This question is part of our collaboration with ACR Convergence 2024 to Continue the Conversation from the meeeting. This question was inspi...

1 Answer available

Do you continue biologics in sJIA patients who develop lung disease on anti IL-1 or anti IL-6 therapies?

This question is part of our collaboration with ACR Convergence 2024 to Continue the Conversation from the meeting. This question was inspired by the ...

2 Answers available